Literature DB >> 33175148

Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention.

Leonardo De Luca1, Marco Valgimigli2.   

Abstract

Percutaneous coronary intervention (PCI) has remarkably evolved in the last decades. This has resulted in a larger number of patients treated with PCI, including those with more complex anatomic lesions. Several studies demonstrated that PCI involving complex lesions is associated with increased rate of procedural complications and adverse clinical outcomes. In this setting, optimal adjunctive antithrombotic regimens still need to be defined. In this review, we sought to summarize and discuss the recent evidence deriving from analyses appraising antithrombotic therapies in patients undergoing complex PCI. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Anticoagulation therapy; Aspirin; Cangrelor; Clopidogrel; Complex PCI; Dual antiplatelet therapy; Rivaroxaban; Ticagrelor; Unfractioned heparin

Mesh:

Substances:

Year:  2021        PMID: 33175148     DOI: 10.1093/ehjcvp/pvaa107

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


  1 in total

1.  Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study.

Authors:  Leonardo De Luca; Paolo Calabrò; Fabio Chirillo; Cristina Rolfo; Alberto Menozzi; Piera Capranzano; Maurizio Menichelli; Elisa Nicolini; Ciro Mauro; Carlo Trani; Francesco Versaci; Fabrizio Tomai; Giuseppe Musumeci; Carlo Di Mario; Martino Pepe; Sergio Berti; Carlo Cernetti; Plinio Cirillo; Diego Maffeo; Giuseppe Talanas; Marco Ferlini; Marco Contarini; Valerio Lanzilotti; Marino Scherillo; Giuseppe Tarantini; Simone Muraglia; Roberta Rossini; Leonardo Bolognese
Journal:  Clin Cardiol       Date:  2022-06-22       Impact factor: 3.287

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.